You are here

Our science / Clinical Trials / Find a Trial / NCT00150332

Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Back to Search Print Save as PDF Bookmark Trial

NCT00150332

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Kamogawa, Chiba, 296-0041 Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Nosocomial Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- infection due to methicillin-resistant Staphylococcus aureus

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- hypersensitivity to linezolid

NCT00150332
Pfizer
Completed
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Respiratory Tract Infections
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
NCT03529773
All Genders
18+
Years
Multiple Sites
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
NCT03313037
All Genders
60+
Years
Multiple Sites
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288
All Genders
0+
Years
Multiple Sites
HIV Infections
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
NCT00002266
All Genders
18+
Years
Tucson, Arizona
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Infections, Nosocomial
Drug: linezolid
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
January 2006
Not Provided

Inclusion Criteria:

  • infection due to methicillin-resistant Staphylococcus aureus

Exclusion Criteria:

  • hypersensitivity to linezolid
Sexes Eligible for Study: All
16 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00150332
M12600067
A5951054
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now